QurAlis to Participate in Piper Sandler 37th Annual Healthcare Conference

Audio By Carbonatix

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 20, 2025--

QurAlis Corporation, a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of neurodegenerative and neurological diseases, today announced that Kasper Roet, Ph.D., CEO and co-founder, will present a company update at the Piper Sandler 37 th Annual Healthcare Conference. Dr. Roet’s presentation is Tuesday, December 2, 2025 at 1:40PM ET. Management will also participate in one-on-one investor meetings.

The QurAlis corporate presentation can be accessed by visiting the presentations section of the Company’s website at www.quralis.com.

About QurAlis Corporation

At QurAlis, we are neuro pioneers on a quest to cure, boldly seeking to translate scientific breakthroughs into powerful precision medicines. We work collaboratively with a relentless pursuit of knowledge, precise attention to craft, and compassion to discover and develop medicines that have the potential to transform the lives of people living with neurodegenerative and neurological diseases. QurAlis is the leader in development of precision therapies for amyotrophic lateral sclerosis (ALS). In addition to ALS, QurAlis is advancing a robust precision medicine pipeline to bring effective disease-modifying therapeutics to patients suffering from severe diseases defined by genetics and clinical biomarkers. For more information, please visit www.quralis.com or follow us on X @QurAlisCo or LinkedIn.

View source version on businesswire.com:https://www.businesswire.com/news/home/20251120380958/en/

CONTACT: Media contact:

Kathy Vincent

[email protected]

310-403-8951

KEYWORD: MASSACHUSETTS UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: BIOTECHNOLOGY GENERAL HEALTH NEUROLOGY HEALTH PHARMACEUTICAL

SOURCE: QurAlis Corporation

Copyright Business Wire 2025.

PUB: 11/20/2025 07:45 AM/DISC: 11/20/2025 07:45 AM

http://www.businesswire.com/news/home/20251120380958/en